text:
Misleading applications, also known as rogue applications, have always tried to lure users into their traps by using various techniques such as fake security scans, misleading task bar notifications, popup windows, etc. To take this to a new level, developers of these applications are now frequently changing the product name and its associated website name in order to mislead users and antivirus vendors. Clones of the same product—with different names—continue to appear almost every day. Earlier this week Symantec published its Report on Rogue Security Software, which discusses misleading apps in greater detail. A couple of examples of rogue security software are given below. We identify one such family of rogue or misleading applications as WiniGuard:
Those who are spreading this particular rogue app hold onto some of the associated domains for up to 24 to 48 hours. Once this domain goes down, another new domain becomes active, which will look almost the same as the original but now with a new name. However, the functionality of all of these clones is essentially the same. Digging further into this scam we found that the owner of domains related to WiniGuard has registered some 60,000+ domains in his name.
At the time of writing this blog, some of them were still active:
Of course, these sites do not provide the software for free. Users are misled to pay for a "subscription" to these fake products in order to remove purported spyware from their machines. The "detections" alleged to be found by these products are bogus and are displayed in an alarmist fashion as an attempt at scaring users into divulging personal information, providing credit card details, and often downloading further malicious software.
The following list is only a selection of the latest names of rogue apps from the WiniGuard family—there are many more out there and new variations are constantly being created:
• WiniGuard
• WiniBlueSoft
• WinBlueSoft
• Winishield
• WiniFighter
• SafeFighter
• SaveKeep
• Savedefense
• SaveArmor
• BlockDefense
• SystemCop
• QuickHealCleaner
• SecurityFighter
• SecurityVeteran
• SecuritySoldier
• SafetyKeeper
• SaveSoldier
• Softsafeness
• SecureWarrior
• TrustCop
• TrustNinja
• TrustWarrior
• TrustSoldier
• TrustFighter
At Symantec we come across many such campaigns for distributing fake antivirus software, such as this recent example. We recommend that users make themselves aware of these scams, which typically show exaggerated warnings, fake scan reports, and redirect users to fraudulent antivirus or Internet security websites.
We also advise users to be cognizant of these scams and always purchase software from legitimate vendor's websites. Symantec detects this particular misleading application as WiniGuard, and advises customers to ensure that their antivirus software and definitions are kept up to date. Please download the Symantec Report on Rogue Security Software for further information on misleading applications.


text:
0cart: $0.00
Previous Page
[x] Close Window
Send your friend(s) a link to this product along with a personal message!
Your Name:
Your E-mail:
To: (your friend's email)
Your Message:
Cc me
Please enter the text below:
Alternate Images:
Overall Rating:
Read all reviews |
Write a review
Item #: 227005
In stock
3 Reviews - Overall Customer Rating:
Show all reviews |
Write a review |
Show reviews with photo(s) |
Show reviews with video(s)
Reviewed by: ds916
(Read all my reviews)
Location: Sacramento, CA
Title: Love!
Date: Aug 01, 2013
These stickers were too big for the lollipops I bought to put them on. I ended up using them to seal the thank you notes.
Report this review as Inappropriate
Was this review helpful to you? Yes | No
Reviewed by: QueenParty
Location: Lakewood, CA
Title: Perfect fit
Date: Feb 07, 2013
These stickers stuck on the suckers well. Price was amazing.
Reviewed by: majac
Title: super cute
Date: Dec 23, 2012
These were super cute and adorable. Used these on little lollipop sticks in cupcakes for an owl themed birthday party. The only negative was that the 'Whoo Whoo" phrase was not ready to just peel and go as the owl stickers. I had to cut each "Whoo Whoo" out separately - just took more time and effort to do.
Show all reviews
© CelebrateExpress.com. All Rights Reserved.CEWEB02

subset: commoncrawl


text:
January 24, 2014
Dawn Van Dam, General Manager of Cambridge Healthtech Associates: The decline in revenue
caused by the patent cliffs, has resulted in the pharma giants slashing their research and development
budgets over the last couple of years. Unfortunately, the resulting slowdown in innovation has left the future looking
bleak for some companies.
In an interview with the
Vice President and Chief Medical Officer at one of the world's leading
international research institutes, we discussed the inability of big
pharmaceutical companies to effectively discover or partner to bring new drugs to the
market, and the consequent issues that this causes in the industry.
Of course, we came to a consensus that if big pharmaceutical companies do not improve their pipeline
of compounds, research and
development will continue to decline in a vicious cycle. The question is, what needs to be done?
Not too long ago, the
pharmaceutical industry was in a stage of rapid innovation. But this has changed. Pharmaceutical companies are now struggling with drug
discovery for several reasons, as outlined below.
All large companies
eventually reach a point where their history creates a foundation of
bureaucracy that tends to prevent innovation. In established organizations, the
avoidance of risk is more important than the need to develop something new -- since
there is already a history of success and financial stability.
Even though startups or
smaller organizations have fewer resources to allocate to research and development,
these businesses traditionally have more successful innovation than large
companies. This is often because scientists are more passionate and hungry to
succeed in smaller organizations. Success in smaller organizations is measured
by the ability to 'stay alive', which often goes beyond the ability to follow
the rules of a large bureaucracy. The future of the small company depends on
the success of the individual and vice versa. Therefore, there is a greater
incentive for employees to work harder and longer hours, and to innovate along
the way.
This realization, combined
with a decrease in overall funding, has led to financial cuts in research and development
programs in the industry. In the past few years, big pharmaceutical companies
have made severe budgetary cuts. According to an article by the Royal
Society of Chemistry, published in 2010, Pfizer, GSK and AstraZeneca were
all looking to decrease their research and development budgets by at least $1 billion in the
next few years. AstraZeneca alone had planned to cut roughly 1,800 research and development
positions, leaving many talented drug development scientist without a job. Unfortunately,
there are not many places for these people to go.
Pharmaceutical expertise
does not translate well to other industries. And, within the industry, generic
firms do not need these scientists, and small pharmaceutical companies do not
have the resources to employ more scientists. A few of these scientists will go
on to start their own companies, but even these will most likely stall when
additional funding is needed. Some scientists will go back to school for a
medical or business degree, while others may leave the industry completely.
In our discussion, the
Vice President and Chief Medical Officer discussed the fact that, generally
speaking, big pharmaceutical companies do not have very good drug pipelines,
with many of their prominent moneymakers having come off patent. During the
interview, this person suggested that once this happens, "it will become
virtually impossible to get something through the first proof of concept, to a
study in man." Although there are plenty of people innovative enough to drive research and development,
the discovery process is bottlenecked by a lack of financing, and the
scientists capable of innovation are not in the position to make new
discoveries due to bureaucracies or other constraints.
The industry is trying
many solutions to identify the "light at the end of the tunnel." For example, with
advancements in genomics and sequencing,
and the addition of sophisticated bioinformatics, everyone is hoping to turn
this field, which appears to be full of opportunities, into commercial success.
By bringing together
leading professionals in the life sciences, Cambridge Healthtech AssociatesTM (CHATM) believes that online communities, such as the Drug Safety
Executive Council (DSECTM) community,
will provide a platform for collaboration and discussion of ideas. Our goal is
to bring conversation and solutions to prominent issues in the industry, like
the one discussed here.
September 18, 2012
Dawn Van Dam, General Manager, Cambridge Healthtech Associates : After interviewing numerous professionals in the life science industry over the past six months, I've seen a common theme emerge: in an ideal world, sharing data with other companies and institutions would allow the development of better technologies and faster solutions. Words like "synergy" and "ecosystem" were used by interviewees to paint a picture of an idealized healthcare landscape in which breakthroughs are accomplished through collaborative efforts - where researchers share both their successes and failures.In reality, however, the industry provides scientists with incentives that understandably keep them from sharing their findings with other industry leaders. Pharma researchers must protect their IP in order to preserve company integrity and maintain job security, and academics need to keep their findings quiet as they vie for the chance to publish. Therefore redundancies are common in research and those coveted breakthrough results don't come along as often as they could!It seems that professionals across the healthcare spectrum - scientists to CEOs - believe that collaboration in research through sharing data and findings is the solution to translate research to the clinic faster. Could increased collaboration in research really help push the industry forward, or is it simply too idealistic for a cut-throat, business-oriented world?Many of the industry professionals who support collaboration in research suggest creating an incentive system that encourages data-sharing. One, a CTO and Head of R&D for a small organization focused in bioinformatics, believes strongly in combining efforts for more efficient research. In an interview for our study, he highlighted the cost/time benefits of collaboration: "I have an impression that many people do the same thing in a slightly different way, and each one with different funding in a different place in the world. So, I have the impression that a lot of energy is actually redundant." Sharing data can ensure that those vital funds aren't being used up by redundant experiments and, instead, are put toward achieving new breakthroughs.Sharing data has benefits for research, but could also have serious implications for the business side of the industry. While redundant research depletes resources throughout the industry, competition within the industry forces researchers to work harder and faster towards making breakthroughs. If collaboration in research and data sharing eliminated the threat of a competitor making an important discovery first, would scientists work more slowly toward scientific discoveries?Perhaps one solution to increase industry efficiency is to develop public-private partnerships, as a CEO and founder of a small European bioinformatics company described. "The [private enterprises] find it difficult to access these data and make use of them to ultimately push forward and develop the best drugs. I think that when you read about good public-private partnerships, where there are these collaborative efforts between the academic world and the private world, that's when it becomes most effective."Industry and academic partnerships allow for data sharing and collaboration in research on a smaller and more manageable scale, while maintaining that competitive edge necessary to drive industry forward at a fast pace. With shared resources and combined funding sources, these partnerships can make greater strides in research and avoid repeating the same mistakes as others in the industry, or drawing redundant conclusions.A contained and organized system, like the public-private partnership, or a consortium, is a small-scale initiative that can encourage collaboration in research and could ultimately help the entire industry function more efficiently.
We would like to acknowledge and thank all of those who provided their thoughts for this six-month study.If you would like more information about how Cambridge Healthtech Associates™ help you form, implement or manage a collaborative project in life sciences research and development, please contact me. We have completed many collaborative projects over the last seven years; consequently, our expertise and experience are unparalleled in the industry.
July 17, 2012
Dawn Van Dam, General Manager, Cambridge Healthtech Associates : Recently, Cambridge Healthtech Associates™ (CHA) completed interviews with preclinical safety experts from large and small biopharmaceutical companies, focusing on middle and senior management levels of preclinical safety/toxicology groups. CHA specializes in conducting evaluations of new technologies in the marketplace and we have completed many technology evaluation projects over the last seven years. We were able to apply our expertise to identify trends in safety biomarker utilization within these top-tier companies. Ernie Bush, PhD, our Scientific Director in drug safety and development, led this ground-breaking research project. Dr Bush has nearly 30 years of biomedical research, focused on preclinical safety assessment and the navigation, evaluation and prioritization of biopharmaceutical research initiatives. Dr Bush's experience in several senior decision-making roles at big pharma was critical for recommendations made as an outcome of this consulting and market research initiative. One key conclusion from the research was that knowing the levels and profiles of various safety biomarkers helps to improve understanding of the mechanism and relevance of the animal studies relative to human clinical safety prediction. Most interviewees found the inclusion of systems or pathway modeling into the selection and interpretation of safety biomarkers to be an attractive new element.As expected, there were considerable differences among companies in which tests they routinely run, and at what stage in the early safety-testing process they run the tests. Despite these differences, in attempting to benchmark current 'early' safety tests in drug discovery - those used routinely by companies (>50% of the time) - we found the following trends:
- Large companies are far more aggressive than smaller companies in terms of the number of tests run, and how early they are run (this trend also reappears below)- Most companies are using physical chemical prediction software, and about half are using DEREK or other forms of gene or DART prediction software. Most companies conduct HCA cell health parameter screening of some form, with the exception of small companies. - Most companies, large and small, did a form of off-target screening (usually CEREP), with smaller companies performing the screens later in the process. - The range of tests run at large and small pharmas was from about 20% of the tests considered, to over 90%, but the average was about 60%.
In a future article, we will discuss additional findings from our safety biomarkers research. In the meantime, if you have questions or would like more information on our research projects, please contact me. We have scientific experts in many areas, including drug safety, next-gen sequencing, genomics, bioinformatics, diagnostics, biomarkers, protein engineering, drug discovery, preclinical safety, high-content analysis, biologics, and more.
March 26, 2012
Dawn Van Dam, General Manager, Cambridge Healthtech Associates : If you are finding us for the first time… welcome. Our vision is for the Drug Safety Executive Council online community to become the platform to both network with peers and exchange ideas related to advancing drug safety solutions. Up until now, membership in the DSEC community has been limited to bio-pharma company employees. To engage a wider audience in the drug safety space, the new DSEC will include members from bio-pharma, along with governmental agencies, academia, CROs and technology providers. I invite you to take a look around the new site, and we welcome your feedback.


text:
Petri Announces May Town Meeting Schedule
Washington, D.C.—U.S. Representative Tom Petri (R-WI) announced the schedule of his upcoming town meetings that will take place throughout the 6th Congressional District in the last week of May. Petri encourages all who are interested to come and share their views in a group setting.
"Town meetings are a fundamental part of our democracy," said Petri, "because it allows me the opportunity to directly communicate with the constituents I represent in Washington.
"I invite everyone to attend one of the sessions so they can share their opinions, ask questions, or engage in a group discussion with other 6th District residents."
Here is the town meeting schedule for May:
Tuesday, May 28
10:30 -11:30 a.m. LODI
Lodi Public Library, 130 Lodi Street
Program Room
2:00 - 3:00 p.m. WESTFIELD
Municipal Building, 129 East Third Street
Room A
4:00 - 5:00 p.m. RURAL WAUTOMA
Dakota Town Hall, N1470 State Road 22
Wednesday, May 29
10:00 - 11:00 a.m. BEAVER DAM
City Hall, 205 South Lincoln Avenue
City Council Chambers
2:00 - 3:00 p.m. PARDEEVILLE
Village Hall, 114 Lake Street
4:30 - 5:30 p.m. RIPON
Ripon Public Library, 120 Jefferson Street
Silver Creek Room
Thursday, May 30
12:30 - 1:30 p.m. NEENAH
City Hall, 211 Walnut Street
City Council Chambers
3:00 - 4:00 p.m. BERLIN
City Hall, 108 North Capron Street
City Council Chambers
Friday, May 31
9:30 - 10:30 a.m. BELGIUM
Village Hall, 195 Commerce Street
2:00 - 3:00 p.m. TWO RIVERS
City Hall, 1717 East Park Street
City Council Chambers
Saturday, June 1
10:00 - 11:00 a.m. SHEBOYGAN
Mead Public Library
710 North 8th Street
Rocca Meeting Room
1:00 - 2:00 p.m. MEQUON
Public Safety Building
11300 North Buntrock Avenue
Police Training Room


text:
Laura Resen
Beachy Dining Room
Designed by Leslie Klotz, this Hamptons dining room features seahorses from a garden antiques store, which create a wow factor. Louis XVI-style dining chairs are covered in a jaunty shade of chartreuse leather and backed in a coral and white print. The table is from Liza Sherman Antiques.


text:
EARLY SIGN-UP DISCOUNT: $3,850 by Jan. 21 (regular price $4,450; $1,500 deposit required by Jan. 21 for discount).
Victoria Falls & Botswana extension: $950.
All prices based on double occupancy.
All accommodations, meals, internal transportation in Zambia (including 3 domestic flights), airport transportation at start and end of trip, park fees, guide fees, laundry, all group activities.
Not Included
Transportation to and from Zambia (but we are happy to help you find the best flights), Zambia visa ($50, obtainable at airport upon arrival) vaccinations or other prophylaxis, trip insurance, drinks, tips.
This trip is a great value.
A Year Later
Remembering our time in Zambia still reliably brings me to a more peaceful, grateful, grounded state. … [read more]
— David M., 2012 (a year later)
We have taken great efforts to find accommodations, transportation, and other facilities that provide the best value for the price. And we have then negotiated the best possible rates.
You will stay in comfortable, often spectacular, accommodations; you will be well fed; you will be well taken care of.
To maintain an intimate group and wildlife viewing experience, the trip is limited to a maximum of 10 participants.


text:
Monday, December 29, 2014
Follow us:
Time Warner Cable video customers:Sign in with your TWC ID to access our video clips.
Sign in
Free Video Views Remaining
To get you to the stories you care about, we are offering everyone 10 video views per month.
Watch Video
Access to our video is always free for Time Warner Cable video customers who login with their TWC ID.
To view our videos, you need to
install Adobe Flash 9 or above. Install now.
Then come back here and refresh the page.
The University of Rochester men's basketball team is getting set for its upcoming game against Ithaca as the NCAA Division III tournament resumes this weekend.
The 22-4 Yellowjackets face 20-8 Ithaca at the Palestra on Saturday night. The winner advances to the Sweet 16.
It will be the final home game for Rochester star John DiBartolomeo. The Division III Player of the Year candidate is the player opposing teams focus on shutting down, but it's the supporting cast that the senior guard credits with his success.
"My teammates get a lot of attention. That's really what opens things up for me. The big men set great screens a lot of times for me and that enables me to get in the lane and make plays. Because of how good our shooters are and our finishers are, they have to respect them and that's why I get to the lane so much and get to the free throw line and the basket," he said.
Personal accomplishments come throughout the year and they're all team awards. The main goal is go as far as we can in the tournament and if we could get to Salem, and Atlanta, that's where our goals lie. That's what we think about and that's what we work for."
Reproduction in whole or in part without permission is prohibited.
© 1999-2014 Time Warner Cable Enterprises LLC. All Rights Reserved.
Web design and web development by Tipit.